Triple-negative breast cancer (TNBC) refers to breast cancer without significant expression of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2. We sought to identify the hub genes and find the potential progression mechanism of TNBC as well as immunotherapeutic targets. First, we screened the overlapped hub genes of Immune and Stromal, and the tumor mutation burden gene sets, as well as the The Cancer Genome Atlas (TCGA)-TNBC data set. Among these hub genes, we performed gene set enrichment analysis (GSEA) and gene set variation analysis analyses to recognize and evaluate the hub genes. Moreover, immune cell infiltration was evaluated by the CIBERSORT algorithm and single-sample GSEA. In addition, the expression and methylation of scavenger receptor class A member 5 (SCARA5) in TNBC were verified by quantitative PCR and methylation-specific PCR. Also, MTT and transwell assays were used to assess the biological function of SCARA5 in TNBC. SCARA5 and CMA1 were listed, and they mainly participated in cancer-related signaling pathways and immune-related signaling pathways. Interestingly, SCARA5 was closely associated with tumor purity and immune cell infiltration. Moreover, we found that SCARA5 was significantly downregulated and hypermethylation was in the promoter of SCARA5 in TNBC tissues. Our study showed the role of SCARA5 in proliferation and migration of TNBC, and suggested that SCARA5 can potentially serve as a candidate immunotherapy target for TNBC.

中文翻译：

---

通过综合分析鉴定SCARA5基因作为三阴性乳腺癌的潜在免疫相关生物标志物。

三阴性乳腺癌（TNBC）是指没有显着表达雌激素受体（ER），孕激素受体（PR）或人类表皮生长因子受体2的乳腺癌。我们试图鉴定集线器基因并发现其潜在的进展机制。 TNBC以及免疫治疗靶标。首先，我们筛选了免疫和基质细胞的重叠中心基因，以及肿瘤突变负荷基因集，以及癌症基因组图谱（TCGA）-TNBC数据集。在这些中枢基因中，我们进行了基因集富集分析（GSEA）和基因组变异分析分析，以识别和评估中枢基因。此外，通过CIBERSORT算法和单样本GSEA评估了免疫细胞浸润。此外，清道夫受体A类成员5（SCARA5通过定量PCR和甲基化特异性PCR验证TNBC中的）。而且，MTT和transwell分析法被用于评估SCARA5在TNBC中的生物学功能。列出了SCARA5和CMA1，它们主要参与癌症相关的信号通路和免疫相关的信号通路。有趣的是，SCARA5与肿瘤纯度和免疫细胞浸润密切相关。此外，我们发现在TNBC组织中，SCARA5被显着下调，而SCARA5的启动子中也存在甲基化过度。我们的研究表明SCARA5在TNBC增殖和迁移中的作用，并建议SCARA5 可以潜在地用作TNBC的候选免疫治疗靶标。